ExcelFin Acquisition Corp.
XFINW
NASDAQ Global Market0.07
USD
-0.08
- -
CIK
0001852749
ISIN
US30069X1101
CUSIP
30069X110
Return %
Stock
S&P500
1Y
99.43
18.21
3Y
-88.33
64.38
5Y
-88.33
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Joseph D. Ragan III
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 473 Jackson Street San Francisco CA United States of America 94111
- CIK
- 0001852749
- Website
- excelfinacquisitioncorp.com
- Similar Companies
- Business
- ExcelFin Acquisition Corp. (NASDAQ: XFIN; XFINW) is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company offers no operational products or services, instead providing a public market platform through its initial public offering proceeds held in trust, sponsor expertise in due diligence and transaction structuring, and access to capital markets for target companies in sectors including healthcare, fintech, technology, media, telecommunications, and related industries. ExcelFin targets established businesses seeking strategic consolidation and value creation without traditional revenue streams of its own. Headquartered in Fort Mill, South Carolina, with prior references to San Francisco, California, the company was founded in 2021 as a Delaware corporation and is a subsidiary of ExcelFin SPAC LLC, sponsored by Grand Fortune Capital, LLC and Fin Capital. In a major development completed on October 1, 2024, ExcelFin merged with Baird Medical Investment Holdings Limited, a microwave ablation medical device developer; the combined entity now trades as Baird Medical Investment Holdings Limited under the Nasdaq tickers BDMD and BDMDW, following shareholder approval with approximately 99.9% of votes in favor and a concurrent $4.9 million convertible preferred investment by Baird Medical founders and ExcelFin's co-sponsor Grand Fortune Capital. The transaction, originally announced in June 2023 at a pro forma enterprise value of about $370 million assuming 50% redemptions, included sponsor commitments to purchase $8.8 million of Baird Medical's debt and was supported by extensions of ExcelFin's completion deadline to July 2025, with minimal redemptions of about 9% at prior shareholder votes. ExcelFin operates principally in the United States with a focus on global opportunities through sponsor networks.